These structures combined with other experimental observations suggest that heparin or other co-factors used to induce Tau aggregation in vitro introduce several limitations that preclude biologically-relevant studies from elucidating the role of Tau aggregation in the pathogenesis of Tauopathies (Fig. 1). This evidence concerns the gene MAPT and tauopathy.